Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Johnson and Johnson
Teva
Harvard Business School
Boehringer Ingelheim
Chubb
Citi
Farmers Insurance
Healthtrust
Dow

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 3,910,924

« Back to Dashboard

Summary for Patent: 3,910,924
Title: 3,4-Dihydrocarbostyril derivatives and a process for preparing the same
Abstract:A novel compound represented by the formula ##SPC1## Wherein R is defined as hereinafter, having a blocking activity on .beta.-adrenergic nerves, a novel intermediate useful for synthesis thereof and processes for preparing the same are disclosed.
Inventor(s): Tamura; Yasumitsu (Takarazuka, JA), Nakagawa; Kazuyuki (Tokushima, JA), Yoshizaki; Shiro (Komatsujima, JA), Murakami; Nanami (Tokushima, JA)
Assignee: Otsuka Pharmaceutical (Tokyo, JA)
Application Number:05/324,905
Patent Claim Types:
see list of patent claims
Compound;

Drugs Protected by US Patent 3,910,924

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 3,910,924

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
47-37181Apr 13, 1972
47-37182Apr 13, 1972

International Patents Family Members for US Patent 3,910,924

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 197270 ➤ Subscribe
Argentina 209575 ➤ Subscribe
Austria 337703 ➤ Subscribe
Austria 337704 ➤ Subscribe
Austria A244373 ➤ Subscribe
Austria A699775 ➤ Subscribe
Australia 475964 ➤ Subscribe
Australia 5438673 ➤ Subscribe
Australia 6338573 ➤ Subscribe
Belgium 794669 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
AstraZeneca
US Department of Justice
McKesson
Boehringer Ingelheim
Queensland Health
Teva
Cipla
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot